Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa
Minimal inhibitory concentrations (MICs) of prulifloxacin were evaluated in comparison with ciprofloxacin, levofloxacin and moxifloxacin against a large collection ( N = 300) of Pseudomonas aeruginosa strains characterised according to the CLSI/NCCLS microdilution method. Additional in vitro tests (...
Saved in:
Published in | International journal of antimicrobial agents Vol. 26; no. 5; pp. 366 - 372 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
London
Elsevier B.V
01.11.2005
Amsterdam Elsevier New York, NY |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Minimal inhibitory concentrations (MICs) of prulifloxacin were evaluated in comparison with ciprofloxacin, levofloxacin and moxifloxacin against a large collection (
N
=
300) of
Pseudomonas aeruginosa strains characterised according to the CLSI/NCCLS microdilution method. Additional in vitro tests (time–kill curves and mutant prevention concentration (MPC) determinations) were carried out. Assuming a susceptibility breakpoint for prulifloxacin identical to that of ciprofloxacin, the new fluoroquinolone emerged as the most potent antibiotic (72% of susceptible strains versus 65%, 61% and 23% for ciprofloxacin, levofloxacin and moxifloxacin, respectively). Time–kill tests at 4× MIC confirmed the pronounced bactericidal potency of the drug against
P. aeruginosa. Amongst the members of the fluoroquinolone class assessed, prulifloxacin produced the lowest MPC values (≤4
mg/L). Our in vitro results indicate that prulifloxacin represents the most powerful antipseudomonal drug available today. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0924-8579 1872-7913 |
DOI: | 10.1016/j.ijantimicag.2005.07.015 |